Tianjin Ringpu Bio-Technology Co Ltd operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Tianjin Ringpu Bio-Technology Co Ltd with three other
companies in this sector in China:
Beijing SL Pharmaceutical Co Ltd
sales of 1.24 billion Chinese Renmimbi [US$195.06 million]
of which 98%
was Pharmaceuticals Industry),
Zhongyuan Union Cell & Gene Engineering Corp Ltd
(868.97 million Chinese Renmimbi [US$136.46 million]
of which 72%
was Stem cell related business), and
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd
(1.11 billion Chinese Renmimbi [US$174.74 million]
of which 97%
was Pharmaceutical manufacture).
During the year ended December of 2017, sales at
Tianjin Ringpu Bio-Technology Co Ltd were 1.05 billion Chinese Renmimbi (US$164.47 million).
increase of 8.0%
versus 2016, when the company's sales were 969.68 million Chinese Renmimbi.
This was the third consecutive year of growth at Tianjin Ringpu Bio-Technology Co Ltd.